These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30842311)

  • 1. New insights into niclosamide action: autophagy activation in colorectal cancer.
    Newton PT
    Biochem J; 2019 Mar; 476(5):779-781. PubMed ID: 30842311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.
    Wang J; Ren XR; Piao H; Zhao S; Osada T; Premont RT; Mook RA; Morse MA; Lyerly HK; Chen W
    Biochem J; 2019 Feb; 476(3):535-546. PubMed ID: 30635359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
    Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
    J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
    Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
    Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
    Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
    Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
    Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
    Mook RA; Wang J; Ren XR; Chen M; Spasojevic I; Barak LS; Lyerly HK; Chen W
    Bioorg Med Chem; 2015 Sep; 23(17):5829-38. PubMed ID: 26272032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.
    Burock S; Daum S; Keilholz U; Neumann K; Walther W; Stein U
    BMC Cancer; 2018 Mar; 18(1):297. PubMed ID: 29544454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular mechanisms of niclosamide antitumor activity].
    Moskaleva EY; Perevozchikova VG; Zhirnik AS; Severin SE
    Biomed Khim; 2015; 61(6):680-93. PubMed ID: 26716739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.
    Li Y; Oliver PG; Lu W; Pathak V; Sridharan S; Augelli-Szafran CE; Buchsbaum DJ; Suto MJ
    Cancer Lett; 2017 Mar; 389():41-48. PubMed ID: 28043913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer.
    Cho YH; Cha PH; Kaduwal S; Park JC; Lee SK; Yoon JS; Shin W; Kim H; Ro EJ; Koo KH; Park KS; Han G; Choi KY
    Oncotarget; 2016 Dec; 7(49):81727-81740. PubMed ID: 27835580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
    Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
    Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
    Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
    Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133
    Klose J; Eissele J; Volz C; Schmitt S; Ritter A; Ying S; Schmidt T; Heger U; Schneider M; Ulrich A
    BMC Cancer; 2016 Nov; 16(1):896. PubMed ID: 27855654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
    Wang LH; Xu M; Fu LQ; Chen XY; Yang F
    Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression.
    Chang X; Zhen X; Liu J; Ren X; Hu Z; Zhou Z; Zhu F; Ding K; Nie J
    Kidney Int; 2017 Sep; 92(3):612-624. PubMed ID: 28318631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.
    Cheng X; Xu X; Chen D; Zhao F; Wang W
    Biomed Pharmacother; 2019 Feb; 110():473-481. PubMed ID: 30530050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of aquaporin-5 sensitizes colorectal cancer cells to 5-fluorouracil via inhibition of the Wnt-β-catenin signaling pathway.
    Li Q; Yang T; Li D; Ding F; Bai G; Wang W; Sun H
    Biochem Cell Biol; 2018 Oct; 96(5):572-579. PubMed ID: 29390193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1
    Chen B; Zhang D; Kuai J; Cheng M; Fang X; Li G
    Tumour Biol; 2017 Jun; 39(6):1010428317715155. PubMed ID: 28639895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.